Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
General Principles of Immunotherapy for Glioblastoma
Background Despite trimodal therapy consisting of maximal safe resection and adjuvant partial radiotherapy with concurrent and subsequent temozolomide, glioblastoma (GBM) has a dismal prognosis, with a median survival of 14.6 months and an overall survival of only 9.8% at 5 years. Further…